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Abstract
Background: Biological agents inhibiting TNF-α and other molecules involved in inflammatory cascade have been
increasingly used to treat rheumatoid arthritis (RA). However, it remains controversial whether biological agents can
be used safely in a patient with an underlying chronic infectious disease.
Case presentation: A 63-year-old woman who had been treated with tocilizumab (TCZ), anti-interleukin-6
receptor antibody, for RA presented to our outpatient clinic due to hemoptysis. She was diagnosed with
pulmonary Mycobacterium avium complex (MAC) infection, and high-resolution computed tomography (HRCT)
showed a single cavitary lesion in the right upper lobe. After diagnosis of pulmonary MAC disease, TCZ was
discontinued and combination chemotherapy with clarithromycin, rifampicin, ethambutol and amikacin was
started for MAC pulmonary disease. Since the lesion was limited in the right upper lobe as a single cavity
formation, she underwent right upper lobectomy. As her RA symptoms were deteriorated around the operation, TCZ
was resumed. After resumption of TCZ, her RA symptoms improved and a recurrence of pulmonary MAC infection has
not been observed for more than 1 year.
Conclusion: This case suggested that TCZ could be safely reintroduced after the resection of a pulmonary MAC lesion.
Although the use of biological agents is generally contraindicated in patients with pulmonary MAC disease, especially
in those with a fibrocavitary lesion, a multimodality intervention for MAC including both medical and surgical approaches
may enable introduction or resumption of biological agents.
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Background
Various types of biological agents such as infliximab and
tocilizumab (TCZ) have been increasingly used to treat
rheumatoid arthritis (RA) because of their effectiveness
[1, 2]. RA patients are often complicated by pulmonary
lesion including interstitial pneumonia and bronchiectasis
that is vulnerable to infection [3, 4]. According to the
recent systematic review, both standard-dose and high-
dose biological agents are associated with the increased
risk of serious infections, compared with traditional
disease-modifying anti-rheumatic drugs (DMARDs) [5].
With respect to the difference in susceptibility between
the classes of biologics, no difference in the risk of infec-
tion has been reported between TCZ and others, although
the Cochrane review in 2011 reported that abatacept,
cytotoxic T lymphocyte antigen 4-immunoglobulin, was
significantly less likely to cause infection than infliximab
and TCZ [6]. Moreover, it has been shown that biological
agents are associated with a significant increase in myco-
bacterial diseases [7]. Concerning the types of mycobacter-
ial diseases, Winthrop and coworkers reported that
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nontuberculous mycobacteria (NTM) infections were
more common than tuberculosis among patients receiving
biologics [8]. Especially in Japan, the most recent nation-
wide survey revealed that the incidence rate of pulmonary
NTM disease (14.7 persons per 100,000 person-years)
may exceed that of tuberculosis in general population, and
that Japan may have one of the highest incidence rates of
pulmonary NTM disease worldwide [9]. Whereas tuber-
culosis can usually be controlled by the standard chemo-
therapy, no effective chemotherapy has been established
against Mycobacterium avium complex (MAC), leading to
aggravation of MAC infection during immunosuppressive
therapy [10, 11]. According to Japanese postmarketing sur-
veillance of TCZ in RA patients, the incidence of NTM in-
fections (0.22 %) is higher than that of tuberculosis (0.05 %)
[12]. Although many of RA patients have underlying pul-
monary lesions and other risk factors for potential NTM in-
fection, it is still controversial whether biological agents can
be a risk of exacerbation of pre-existing pulmonary NTM
disease [11]. Consequently, a strategy for the management
of NTM in RA patients subjected to treatment with bio-
logics remains to be established.
In this report, a case of pulmonary MAC disease in an
RA patient who successfully resumed TCZ after the re-
section of a single cavitary lesion is presented. Although
the use of biological agents is generally contraindicated
in patients with pulmonary MAC disease, especially in
those with a fibrocavitary lesion, a multimodality
approach for MAC may enable introduction or resump-
tion of biological agents. This report is in compliance
with the Helsinki Declaration.
Case presentation
In September 2013, a 63-year-old woman was referred
to our outpatient clinic due to hemoptysis and a pul-
monary lesion on high-resolution computed tomography
(HRCT). Her height was 165.0 cm and body weight was
46.0 kg. The patient never smoked but had a medical
history of Crohn’s disease, which remained in remission,
and RA that was diagnosed in 2010 according to the
criteria of the American College of Rheumatology. She
had been treated with prednisolone (PSL) (5 mg/day)
and methotrexate (12 mg/week). Because the disease
activity was not properly controlled with these medica-
tions, methotrexate was stopped and 360 mg of TCZ
was administered intravenously once every 4 weeks from
October 2011. At this time, the visual analogue scale
(VAS) was 37 mm and the disease activity score (DAS)
28–C-reactive protein (CRP) was 3.81. When TCZ was
introduced, her chest radiograph was normal (Fig. 1a),
but HRCT showed a small nodular shadow in the right
upper lobe of the lung (Fig. 1b). Although the patient
had no respiratory symptoms with no pathogenic
bacteria isolated from the sputum, she was prescribed
400 mg/day clarithromycin (CAM) as a monotherapy
before her referral to our department. Two years after
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Fig. 1 Serial changes on chest X-ray and chest computed tomography findings. a Chest X-ray taken immediately before starting tocilizumab (TCZ),
showing subtle nodular infiltrates. b CT scan taken immediately before starting TCZ, showing a small nodular shadow in the right upper
lobe (arrowhead). c Chest X-ray taken when the patient developed hemoptysis 2 years after starting TCZ, showing infiltration and cavity
formation in the right upper lung field (arrowhead). d CT scan taken when the patient developed hemoptysis 2 years after starting TCZ,
showing consolidation, cavity formation, bronchiectasis, and centrilobular nodules in the right upper lobe (arrowhead)
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the initiation of TCZ, she was admitted for hemoptysis,
and a chest radiograph showed infiltration and cavity
formation in the right upper lobe (Fig. 1c). HRCT also
showed consolidation, cavity formation, bronchiectasis,
and centrilobular nodules in the right upper lobe
(Fig. 1d). When admitted, her body temperature was
36.4 °C. Coarse crackles were auscultated over the right
upper lung field and joint pain was positive in her left
wrist, right elbow, and metatarsophalangeal joints of the
right third and fourth toes. There were no abnormal
findings on complete blood counts and biochemistry tests
except for mild leukocytopenia (white blood cells,
3300/μL) (Table 1). The anti-glycopeptidolipid core IgA
antibody was positive (2.44 U/mL), and the QuantiFERON®
TB Gold test was negative. Pulmonary MAC disease was
diagnosed because the sputum culture was positive for
MAC twice. A Broth MIC® NTM showed that the isolated
MAC was sensitive to CAM (minimum inhibitory concen-
tration, 1 μg/mL) despite 2-year monotherapy with CAM.
Combination chemotherapy with 800 mg/day of CAM,
450 mg/day of rifampicin (RFP), 500 mg/day of ethambutol
(EB), and thrice weekly intravenous amikacin (600 mg/per
dose) were started. Because TCZ might have contributed to
the exacerbation of the pulmonary MAC disease, TCZ
therapy was discontinued after the diagnosis of pulmonary
MAC disease. In addition, PSL was tapered to 2 mg/day,
and nonsteroidal anti-inflammatory drugs were started for
RA. At this time, the disease activity of her RA was
relatively stable (VAS, 6 mm; DAS 28-CRP, 1.99).
Although 3 months of anti-MAC treatment improved
the consolidation and centrilobular nodules, the cavitary
lesion and bronchiectasis were still significant on chest
X-ray and HRCT (Fig. 2a, b). Her right upper lobe was
resected (Fig. 3), since her lesion was limited to a single
lobe and the cavitary lesion seemed refractory to drug
therapy. As expected, tissue culture of the resected spe-
cimen tested positive for MAC. Although her pulmonary
MAC lesion was totally removed with the operation and
microbiological examinations remained negative, CAM,
RFP, and EB were continued to prevent a relapse of
MAC pulmonary disease. Because she reported deterior-
ation of her joint symptoms around the time of the
operation (VAS, 38 mm; DAS 28-CRP, 4.07), TCZ was
resumed 1 month after resection.
Two months after the restarting of TCZ, her joint
symptoms had totally improved; the VAS improved from
38 to 3 mm, and DAS 28-CRP improved from 4.07 to
1.06. In terms of the pulmonary MAC disease, no new
lesion was found by HRCT at 1 year after the resump-
tion of TCZ (Fig. 2c, d).
Conclusions
MAC is one of the most common opportunistic patho-
gens in RA patients on biological agents [13]. Although
most immunocompetent patients with MAC infection
maintain a stable clinical course for years, immunocom-
promised patients often show rapid progression of the
disease. Previous MAC infections in RA patients are a
particularly controversial issue, because the aggravation
of MAC infection requires abandoning effective treat-
ment with biological agents [11, 14]. However, some case
reports and the new joint statement published by the
Japanese Respiratory Society (JRS), Japan College of
Rheumatology (JCR), and Japanese Society for Tubercu-
losis (JSTB) in 2014 proposed that, in certain RA
patients with pulmonary MAC disease, biological agents
can be safely used in combination with chemotherapy
for pulmonary MAC disease [15, 16]. In the case series
Table 1 Laboratory findings on admission
Complete blood count
White blood cells 3300/μL
Band cells + Seg cells 54.1 %
Lymphocytes 32.7 %
Monocytes 8.1 %
Eosinophil granulocytes 4.5 %
Basophil granulocytes 0.6 %
Hemoglobin 13.8 g/dL
Mean corpuscular volume 94/fL
Platelets 182 × 103 /μL
Biochemistry
Total protein 6.4 g/dL
Albumin 4.2 g/dL
Total bilirubin 0.7 mg/dL
Glutamic oxaloacetic transaminase 20 IU/L
Glutamic pyruvic transaminase 14 IU/L
Lactate dehydrogenase 180 IU/L





Alkaline phosphatase 197 IU/L
Gamma-glutamyl transferase 13 IU/L
Serological studies
C-reactive protein 0.01 mg/dL
Matrix metalloproteinase 3 42.2 ng/mL
β-D-glucan <3.0 pg/mL
Aspergillus antigen 0.0 COI
Cryptococcus antigen 0.0 COI
QuantiFERON® TB Gold test Negative
Anti-glycopeptidolipid core IgA antibody 2.44 U/mL
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by Mori and colleagues, anti-TNF agents could be safely
reintroduced in seven patients without exacerbation of
the MAC infection [14]. Nakahara and coworkers also
described a case of successful reintroduction of TCZ
without aggravation of MAC infection under the stand-
ard chemotherapy [15]. However, there has been no
report of surgical resection of MAC lesion followed by
successful reintroduction of biologics. In this regard, this
is the first case report which indicates that biological
agents might be safely resumed after surgery.
In this case, HRCT taken before the initiation of TCZ
treatment showed small nodular opacity in the right
upper lobe, suggesting pre-existing MAC disease. Since
monotherapy with macrolides can induce macrolide-
resistance, it is not an appropriate treatment in the pres-
ence of MAC disease [17]. Therefore, bronchoscopy
should have been performed to make a diagnosis of
pulmonary MAC disease so that combination chemo-
therapy could be introduced at an earlier time point.
After the exacerbation of pulmonary MAC disease,
HRCT showed consolidation, cavity formation, bronchi-
ectasis, and centrilobular nodules that were localized
only in the right upper lobe. According to the JSTB
statement about the resection of pulmonary NTM
disease, a single cavity lesion is a good candidate for
surgery to suppress the activity of pulmonary NTM
disease [18]. From this standpoint, our approach to
eradicating MAC lesions was appropriate.
According to the recent joint statement, patients with
NTM are in principle prohibited from using biological
agents [18]. The statement also mentioned that using
biological agents could be considered with full evalu-
ation of the risk and benefit, only in the following cases:
(i) the causative pathogen is MAC; (ii) the radiographic
features are of the nodular/bronchiectatic type; (iii) the
existing pulmonary lesion is limited; (iv) the patient’s
general performance status is good; (v) chemotherapy
against NTM could be given in the long term with a
good treatment response; and (vi) biological agents are
strongly needed because of the high disease activity of
RA. It also stated that using biologics in those with a
fibrocavitary lesion of NTM is a contraindication [18].
The present case indicated the possibility of safe reintro-
duction of biological agents after resection, even in cases
with a fibrocavitary lesion, when the cavitary lesion is
localized in a single lobe. Since no difference in the risk of
infection has been reported between TCZ and other bio-
logical agents [7], we considered that this strategy might
be applied not only for TCZ but also for other biologics.
One of the discussion points is the validity of surgi-
cal resection against MAC disease. In this case, her
hemoptysis disappeared after 3 months of chemother-
apy and the infiltrates around the cavity were also
resolved. However, the cavitary lesion, which could
discharge mycobacteria and might predispose the pa-
tient to later recurrence, was not changed. In general,
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Fig. 2 Serial changes on chest X-ray and chest computed tomography findings. a Chest X-ray taken 3 months after chemotherapy against
Mycobacterium avium complex (MAC), showing improved infiltration (arrowhead). b CT scan taken 3 months after chemotherapy against MAC,
showing diminished consolidation and centrilobular nodules in the right upper lobe (arrowhead). c Chest X-ray taken 1 year after resuming
TCZ, showing no abnormal findings other than the postoperative findings after the right upper lobectomy. d CT scan taken 1 year after resuming TCZ,
showing no postoperative findings of right upper lobectomy
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the cavitary lesion of MAC patients is difficult to be
resolved by chemotherapy alone and is good indica-
tion for surgical resection [18, 19]. Especially for this
patient with high disease activity of RA, we thought it
reasonable to remove the cavitary lesion surgically in
order to resume biological agents.
Another discussion point is the duration of concurrent
chemotherapy against MAC as well as perioperative
chemotherapy. It was possible to discontinue the chemo-
therapy against MAC when the MAC lesion was totally
removed by surgery. However, it was assumed that
chemotherapy should be continued to prevent the
growth of minimal MAC lesion, which was undetectable
by HRCT. A retrospective review of pulmonary resection
in patients with NTM showed that postoperative chemo-
therapy might contribute to decreasing the relapse rate
[20]. The JSTB statement about the resection of
pulmonary NTM disease also recommended postopera-
tive adjuvant chemotherapy [18]. In any case, careful
follow-up to monitor the re-emergence of the MAC
lesion or other opportunistic infections is needed as long
as the patient is receiving biological agents.
In conclusion, an RA case for which TCZ was safely
reintroduced after resection of the pulmonary MAC
lesion was presented. Although the use of biological
agents is generally contraindicated in patients with
pulmonary MAC disease, especially with a fibrocavitary
lesion, a multimodality approach for MAC may be
considered in order to use biological agents safely.
Consent
Written informed consent was obtained from the patient
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Fig. 3 Photograph and photomicrographs of the lung. a Photograph of a cross-sectional specimen from the resected right upper lung.
b Photomicrographs showing an epithelioid granuloma with necrosis (bar, 5 mm). c Photomicrographs showing an epithelioid granuloma
with necrosis (bar, 500 μm). d Photomicrograph showing Langhans giant cells (arrowheads) and epithelioid cells (arrow) (bar, 100 μm)
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